期刊
TWIN RESEARCH AND HUMAN GENETICS
卷 12, 期 3, 页码 269-275出版社
CAMBRIDGE UNIV PRESS
DOI: 10.1375/twin.12.3.269
关键词
ovarian cancer; serous; basic fibroblast growth factor; polymorphisms; FGF2
资金
- National Health and Medical Research Council of Australia [199600]
- U.S. Army Medical Research and Materiel Command [DAMD17-01.4-0729]
- Cancer Council Tasmania and Cancer Foundation of Western Australia
- NIH [R01 CA122443, R01 CA1.12523, R01 CA87S38]
- Mayo Foundation
- California Cancer Research Program [00-01389V-20170, 2110200]
- U.S. Public Health Service [CA14089, CA170S4, CA611.32, CA63464, N01-PC-67010, R03CA113148]
- California Department of Health Services [050-E8709]
Fibroblast growth factor (FGF)-2 (basic) is a potent angiogenic molecule involved in tumor progression, and is one of several growth factors with a central role in ovarian carcinogenesis. We hypothesized that common single nucleotide polymorphisms (SNPs) in the FGF2 gene may alter angiogenic potential and thereby susceptibility to ovarian cancer. We analyzed 25 FGF2 tgSNPs using five independent study populations from the United States and Australia. Analysis was restricted to non-Hispanic White women with serous ovarian carcinoma (1269 cases and 2829 controls). There were no statistically significant associations between any FGF2 SNPs and ovarian cancer risk. There were two nominally statistically significant associations between heterozygosity for two FGF2 SNPs (rs308379 and rs308447; p < .05) and serous ovarian cancer risk in the combined dataset, but rare homozygous estimates did not achieve statistical significance, nor were they consistent with the log additive model of inheritance. Overall genetic variation in FGF2 does not appear to play a role in susceptibility to ovarian cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据